louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04921579: Evaluation of Treatment Duration of En-masse Versus Two Steps Retraction in Patients Having Maxillary Protrusion
Official title: Evaluation of Treatment Duration of En-masse Versus Two Steps Retraction in Patients Having Maxillary Protrusion: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bimaxillary Protrusion
Keywords: En-masse retraction
two step retraction
friction
retraction time
Dental models
Lead sponsor: Future University in Egypt
Sponsor class: OTHER
First posted: 2021-06-10
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Brief summary: there's a scarcity in literature concerning time needed to retract anterior segment following premolars extraction. the purpose of this study is to determine, in orthodontic patients with maxillary protrusion, which form of technique of retraction offers a faster treatment duration of retraction : en-masse or two step techniques

Detailed description: Anterior segment retraction can be done in one of two ways: through En masse or two step techniques. Both are viable options, but, ideally, the investigator wanted to retract and complete the orthodontic treatment as quickly as possible, in order to decrease the negative effects that may occur during treatment. Which of these techniques results in a decreased treatment time is still up for debate.

Eligibility criteria: Inclusion Criteria:

* Adults and adolescent patients ( both gender)
* Age range (14- 24)
* patient with maxillary protrusion requiring first premolars extraction ( bimaxillary protrusion or class II division 1 cases)
* patients with fully erupted permanent teeth ( not necessarily including the third molar).
* cases required maximum anchorage during retraction.
* good general and oral health

Exclusion Criteria:

* patients suffering from any systemic diseases interfering with tooth movement.
* patients with extracted or missing permanent teeth (except for third molars).
* patients with badly decayed teeth.
* patients with any parafunctional habits ( i.e. Bruxism, tongue thrusting, mouth breathing, etc.,.....)
* patients with previous orthodontic treatment

Primary outcomes:
measure: Time to close extraction space
timeFrame: from pre to post retraction ( an average of 10 - 12 months)
Secondary outcomes:
measure: Anchorage loss
timeFrame: From pre to post retraction ( an average of 10- 12 months)
measure: pain of intervention
timeFrame: From pre to post retraction ( an average of 10 - 12 months)
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Future University
Study officials:
affiliation: Future University in Egypt
name: Yehia Mostafa, professor and chairman
role: STUDY_DIRECTOR
References:
Clinical trial NCT00747279: Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke
Official title: Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Acute Ischemic Stroke
Lead sponsor: Hospital Sao Domingos
Sponsor class: OTHER
First posted: 2008-09-05
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this prospective randomized controlled trial was to compare intensive insulin therapy with a carbohydrate restrictive strategy in patients with acute ischemic stroke evaluating the outcome through the Glasgow Outcome Scale Extended, hospital mortality and NIHSS during the ICU stay.


Eligibility criteria: Inclusion Criteria:

* Adult patients with acute ischemic stroke defined as: Abrupt onset of focal neurologic deficit
* No evidence of intracranial hemorrhage at non-contrasted CT scan.

Exclusion Criteria:

* Age below 18
* Pregnancy

Primary outcomes:
measure: Neurological outcome through the Glasgow Outcome Scale Extended
timeFrame: At least 4 months after hospital discharge
Secondary outcomes:
measure: NIHSS during ICU stay
timeFrame: ICU stay
measure: Hospital mortality
timeFrame: Hospital stay
Other outcomes:
Locations:
city: Sao Luis
country: Brazil
facility: Hospital Sao Domingos
state: MA
Study officials:
References:
Clinical trial NCT03085979: Mixed Urinary Incontinence Surgical Trial
Official title: Surgical Management of Mixed Urinary Incontinence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Med: Urinary Incontinence (Stress, Urge, Mixed)
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2017-03-22
Enrollment: 198
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Surgical management of mixed urinary incontinence

Detailed description: Study to evaluate role of anti-incontinent surgery Burch colposuspension Tension free vaginal tape Trans obturator tape for the management of mixed urinary incontinence .

Eligibility criteria: Inclusion Criteria:

* patients with Mixed urinary incontinence

Exclusion Criteria:

Women with associated gynecological surgery e.g. uterine prolapse, previous anti-incontinence surgery, intrinsic sphincter deficiency (ISD), and medical disorders affecting the bladder innervation as diabetes mellitus were excluded from the study. Women who improved on medical treatment with persistence of stress element only were also excluded.

Primary outcomes:
measure: cure of Mixed incontinence
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Fellow of OBS/GYN
name: Hamdy HA Ahmed Saaid, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04044079: Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients
Official title: Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Office Hysteroscopy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-08-02
Enrollment: 150
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the effectiveness of vaginal dinoprostone and vaginal misoprostol with placebo in minimizing the pain experienced by postmenopausal patients during diagnostic ofﬁce hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

Detailed description: hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. Cervical ripening is made possible by the use of medication through different routes. The most commonly used agent is misoprostol, a synthetic prostaglandin E1 (PGE1) analog that is frequently administered in off-label use in obstetrics and gynecology for medical abortion, labor induction, endometrial biopsy, dilatation and curettage, intrauterine device insertion, myomectomy, postpartum hemorrhage, and cervical ripening. In contrast, dinoprostone, a natural PGE2, is mostly used in obstetrics for cervical ripening and the stimulation of uterine contractions to induce labor.

Eligibility criteria: Inclusion Criteria:

* Menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding or abnormal ultrasound ﬁndings)

Exclusion Criteria:

* Nulliparous patients
* patients with cervical pathology
* retroverted uterus (detected by transvaginal ultrasound)
* previous cervical surgery
* patients with severe vaginal bleeding
* allergy or contraindications to dinoprostone or misoprostol therapy (asthma, liver, kidney, or heart disease).

Primary outcomes:
measure: Intensity of pain
timeFrame: an expected average of 10 minutes
Secondary outcomes:
measure: Intensity of pain
timeFrame: 30 minutes after the procedure
measure: Operative time
timeFrame: an expected average 10 minutes
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Ahmed Samy
Study officials:
affiliation: Cairo University
name: AHMED SAMY
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06435884: Long-Term Follow-up of Adult With Atorpphic Scars Treated With TRTP-101
Official title: Long-Term Follow-up of Adult With Atrophic Scars Treated With TRTP-101 in Study CIC101-01
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Atrophic Scar
Lead sponsor: CellinCells
Sponsor class: INDUSTRY
First posted: 2024-05-30
Enrollment: 6
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with Atropic Scars Treated with TRTP-101 in Sutdy CIC101-01

Brief summary: CIC101-01-LT is a long-term follow-up study of subjects treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101.

Detailed description: The long-term safety of TRTP-101 was evaluated by participants in the CIC101-01 clinical trial and followed up for 5 years for serious adverse events.

Eligibility criteria: Inclusion Criteria:

* Received TRTP-101 in clinical trial CIC101-01
* Provided written informed consent to participate in this study

Exclusion Criteria:

* Judged to be unsuitable to participate in this long-term follow-up

Primary outcomes:
measure: Serious Adverse Event
timeFrame: Up to 5 years
Secondary outcomes:
measure: Mean percent change in atrophic scar volume
timeFrame: 6, 12, 18 and 24 months
measure: Patient's Satisfaction
timeFrame: 6, 12, 18 and 24 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine
name: JongHee Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05683184: OMAR Opioid Use Disorder
Official title: Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Control
Opioid Use Disorder
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2023-01-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Detailed description: The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand \[11C\] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.

Eligibility criteria: Inclusion Criteria:

* Able to provide informed consent
* Male and female 18 years and older
* DSM-5 diagnosis of opioid use disorder (for OUD group)
* Physically healthy i.e., no clinically unstable medical conditions
* Written informed consent and have capacity to consent and comply with study procedures

Exclusion Criteria:

* Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
* Presence of ferromagnetic metal in the body or heart pacemaker
* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
* Are claustrophobic

Primary outcomes:
measure: CB1R Availability
timeFrame: One time within 4 weeks of screening
Secondary outcomes:
measure: Serum Endocannabinoid Levels
timeFrame: One time within 4 weeks of screening
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Connecticut Mental Health Center, Clinical Neuroscience Research Unit
state: Connecticut
Study officials:
affiliation: Yale University
name: Anahita Bassir Nia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00711984: Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis
Official title: Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Renal Artery Stenosis
Keywords: renal artery stenosis
stent
comparison of treatments
progression
atherosclerosis
peripheral artery disease
major cardiovascular events
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2008-07-09
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Renal artery stenosis (RAS) usually refers to a disease of the large extra-renal arterial vessels and most frequently is caused by atherosclerotic obstructions. The prevalence of atherosclerotic RAS increases with age, male gender, traditional cardiovascular risk factors (hypertension, diabetes, smoking, hyperlipidemia) and atherosclerotic comorbidities like coronary artery or peripheral artery disease (PAD). A prevalence up to 40% has been reported in patients with PAD. Undoubtedly, atherosclerotic RAS is a progressive disease, as more than half of the patients exhibit an increasing degree of stenosis within five years after diagnosis, and one out of five patients with a critical stenosis (\>60%) suffers renal atrophy and renal failure during this period. RAS may be treated conservatively by so called best medical treatment, surgically, or by endovascular interventions using balloon angioplasty and stenting.

The purpose of the investigators study is to determine the incidence and the predictors of RAS in patients with PAD, and to compare the effect of renal artery stenting versus best medical treatment in patients with hypertension and ostial renal artery stenosis in a randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* PAD and unilateral ostial \>60% RAS and hypertension

Exclusion Criteria:

* Conditions which imply RAS stenting (bilateral significant renal disease, single functioning kidney, or patients whose conditions cannot be managed medically or by intervention)
* Allergy to contrast agents or medication administered for best medical treatment (in particular ASA and statins)

Primary outcomes:
measure: change in mean blood pressure and renal function occurrence of major cardiovascular events
timeFrame: 3, 6, 9, 12 months, annually
Secondary outcomes:
measure: progression of the degree of RAS in the conservative group and restenosis rate in the stent group
timeFrame: 6, 12 months, annually
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University Vienna
Study officials:
References:
Clinical trial NCT01199484: Specific Oral Tolerance Induction to Cow's Milk Allergy
Official title: Specific Oral Tolerance Induction as an Useful Treatment in Two-year-old Children With Cow's Milk Allergy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Hypersensitivity
Keywords: Cow's milk allergy
food allergy
oral desensitization
randomized trial
specific oral tolerance induction.
Lead sponsor: ValenciaUGH
Sponsor class: UNKNOWN
First posted: 2010-09-13
Sex: ALL
Minimum age (years): 24
Maximum age (years): 36
Standard ages: CHILD
Accepts healthy volunteers: no

Brief summary: Background: Limited published evidence shows specific oral tolerance induction (SOTI) to be a potential intervention option for cow's milk proteins (CMPs) allergy. Our hypothesis is that SOTI should be started early in order to improve its efficacy and prevent CMPs sensitization from evolving towards persistent allergy. The aim of this study was to evaluate the safety and efficacy of SOTI in 2-year-old children with cow's milk allergy, as a treatment alternative to elimination diet.

Methods: A total of 60 children between 24-36 months of age with IgE-mediated allergy to CMPs were included in this multicenter study and were randomly divided into two different groups. Thirty children (group A: treatment group) began SOTI immediately, whereas the remaining 30 (group B: control group) were kept on a milk-free diet and followed-up on for one year.


Eligibility criteria: Inclusion Criteria:

1. -Infants between 24-36 months of age.
2. -IgE-mediated allergy to CMPs meeting all the following diagnostic criteria:

   * Immediate-type clinical manifestations, skin (urticaria, angioedema and/or erythema), digestive (acute vomiting and/or diarrhea) or respiratory (bronchospasm and/or rhinitis) involvement in the first two hours after cow's milk ingestion.
   * Skin test readings ≥ 3 mm and specific IgE titers \> 0.35 kU/l for whole cow's milk or someone of isolated CMPs (casein, alpha-lactalbumin, beta-lactoglobulin )
3. -Persistence of CMP allergy in the four weeks prior to tolerance induction, based on the following criteria:

   * Skin (prick) test readings ≥3 mm and specific IgE titers (CAP-FEIA) \>0.35 kU/l for whole cow's milk or someone of isolated CMPs (casein, alpha-lactalbumin, beta-lactoglobulin )
   * Double-blind placebo-controlled challenge (DBPCFC) positive to cow's milk.
4. -Written informed consent from the parents.

Exclusion Criteria:

1. -Clinical manifestations of anaphylactic shock after the ingestion of cow's milk.
2. -Non-IgE-mediated or non-immunological adverse reactions to cow's milk.
3. -Malignant or immunopathological diseases and/or severe primary or secondary immune deficiencies.
4. -Patients receiving immunosuppressor therapy.
5. -Patients receiving beta-blockers (including topical formulations).
6. -Associated diseases contraindicating the use of adrenalin: cardiovascular disease or severe hypertension

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Allergy Unit. University General Hospital
Study officials:
References:
Clinical trial NCT04745884: A Study to Detect Progression of Mass Effect from Unilateral Brain Lesions
Official title: Early Non-invasive Detection of Progression of Mass Effect from Unilateral Brain Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non-traumatic Hemispheric Brain Lesions
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-02-09
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this research is to gather information on the safety and effectiveness of the Brain4Care device for measuring intracranial pressure without invasive procedures.


Eligibility criteria: Inclusion Criteria:

* Adult patients with non-traumatic hemispheric brain lesions deemed at risk for progression of mass effect and possible subfalcine and/or uncal herniation.
* Patients admitted the Neuroscience ICU for serial neurological monitoring.
* Patients whose care is not expected to include immediate surgical decompression.

Exclusion Criteria:

* Patients under the age of 18.
* Patients who are unable to provide consent due to neurologic deficit and does not have a surrogate decision maker available to provide consent.

Primary outcomes:
measure: Functional outcome
timeFrame: 3 months
Secondary outcomes:
measure: Imaging utilization
timeFrame: within ICU admission
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Alejandro Rabinstein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02950584: Surface Roughness of Heat Cured Acrylic Resin Versus Acrylic Resin With Titanium Dioxide
Official title: The Surface Roughness of Rapid Heat Cured Acrylic Resin Versus Modified Conventional Acrylic Resin With Titanium Dioxide Nanoparticles in Maxillary Single Dentures: A Randomized Clinical Trials
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Denture Stomatitis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2016-11-01
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Measurement of surface roughness of tow different material of denture base to find out which material is more hygienic by decreasing the amount of bacterial accumulation.

Detailed description: Using a denture base material as a standard value which is the rapid heat cured acrylic resin and compare it with a new material which is a conventional acrylic resin with addition of titanium dioxide nano particles in surface roughness and measuring it by a device called stylus profilometer this will be done on 20 patients this trial will take about 6 months.

Eligibility criteria: Inclusion Criteria:

1. Completely edentulous maxillary arch and fully dentate mandibular arch with adequate interarch space.
2. The edentulous ridges should be covered by firm healthy mucosa.
3. Angle class I maxillomandibular relationship
4. Healthy and co-operative patients

Exclusion Criteria:

1. Patients with bad habits as severe clenching or bruxism, drug or alcohol addiction, moderate or heavy smoking (greater than 10 cigarettes/day).
2. Previous history of radiotherapy or chemotherapy.
3. Any skeletal problem dictates surgical intervention

Primary outcomes:
measure: The Surface Roughness of the denture base will be measured and reported in micrometer unit
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: